HANSA MEDICAL AB ORD overview

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference PR Newswire LUND, Sweden, Jan. 7, 2025 LUND, Sweden , Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43 rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at [email protected] . The Company has achieved several key milestones in the last 12-months across its three key...

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome PR Newswire LUND, Sweden, Dec. 17, 2024 LUND, Sweden , Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment...

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease PR Newswire LUND, Sweden, Dec. 5, 2024 Data from the trial is expected to be shared in 2025 LUND, Sweden , Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a...

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome PR Newswire LUND, Sweden and EVRY, France, Dec. 3, 2024 The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France , Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and...

Hansa Biopharma to Attend Truist Securities BioPharma Symposium PR Newswire LUND, Sweden, Oct. 30, 2024 LUND, Sweden , Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY . Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications'...

Hansa Biopharma to Attend Truist Securities BioPharma Symposium PR Newswire LUND, Sweden, Oct. 30, 2024 LUND, Sweden , Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY . Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications'...

Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results PR Newswire LUND, Sweden, Oct. 17, 2024 Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance LUND, Sweden , Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results. Søren Tulstrup, President and CEO, Hansa Biopharma said, "The third quarter of...

Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results PR Newswire LUND, Sweden, Oct. 17, 2024 Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance LUND, Sweden , Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results. Søren Tulstrup, President and CEO, Hansa Biopharma said, "The third quarter of...